Southpoint Capital Advisors LP Insider Trading Activity

Average Profitability
14.67%
Insider Buys Quantity
3
Insider Buys Sum
$22.5M
Insider Sells Quantity
1
Insider Sells Sum
$4.57M

Insider Activity of Southpoint Capital Advisors LP

According to the SEC Form 4 filings, Southpoint Capital Advisors LP, being in a position of

  1. 10 percent owner at Fennec Pharmaceuticals Inc.,
    оver the last 12 months, has bought 0 shares, and sold 1265359 shares for $9.71M,
    over all time since 2010-02-22, has bought 400080000 shares for $22.5M, and sold 84340473 shares for $14.91M.

Biography of Southpoint Capital Advisors LP

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$9,705,6734100

Comparison of Insiders on Amount of Buys and Sells

2025-12-24SaleFennec Pharmaceuticals Inc.
FENC
10 percent owner
1M
3.5493%
$7.50$7.5M+20.47%
2025-11-18SaleFennec Pharmaceuticals Inc.
FENC
10 percent owner
19,341
0.0705%
$8.79$170,048+1.26%
2025-11-17SaleFennec Pharmaceuticals Inc.
FENC
10 percent owner
85,918
0.3133%
$8.79$755,193+1.14%
2025-11-14SaleFennec Pharmaceuticals Inc.
FENC
10 percent owner
160,100
0.606%
$8.00$1.28M+12.15%
2025-10-09SaleFennec Pharmaceuticals Inc.
FENC
10 percent owner
20,609
0.0751%
$9.35$192,614-9.54%
2025-10-08SaleFennec Pharmaceuticals Inc.
FENC
10 percent owner
19,605
0.0733%
$9.47$185,722-8.46%
2025-10-07SaleFennec Pharmaceuticals Inc.
FENC
10 percent owner
26,900
0.099%
$9.59$257,893-10.97%
2020-05-04PurchaseFennec Pharmaceuticals Inc.
FENC
10 percent owner
80,000
0.3283%
$6.25$500,000+14.67%
2010-06-08SaleFennec Pharmaceuticals Inc.
FENC
10 percent owner
83.01M
14.9832%
$0.06$4.57M
2010-04-30PurchaseFennec Pharmaceuticals Inc.
FENC
10 percent owner
400M
72.201%
$0.06$22M
2010-02-22PurchaseFennec Pharmaceuticals Inc.
FENC
10 percent owner
0
–
$0$0
2008-08-27PurchaseNexMetals Mining Corp.
NEXM
10 percent owner
6.36M
1.8241%
$0.25$1.61M
Total: 12
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.